ZCM
CTSO icon

Zebra Capital Management’s Cytosorbents Corp CTSO Stock Holding History

Zebra Capital Management’s Portfolio CTSO Stock Details CTSO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-11,297
Closed -$87K – 228
2020
Q1 		$87K Buy
+11,297
New +$57K 0.14% 188

Other funds holding CTSO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Skylands Capital Milwaukee, Wisconsin $763M AUM 26.49% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Zebra Capital Management's CTSO Position: Q2 2020 in Review

Zebra Capital Management sold out of Cytosorbents Corp (CTSO) in Q2 2020, closing a stake of 11,297 shares — an estimated $87K sold.

Zebra Capital Management first reported a position in CTSO in Q1 2020 and held it in 1 quarter. The position peaked at $87K in Q1 2020. 91 funds tracked by Wall St. Rank hold CTSO as of Q2 2020.

  • Zebra Capital Management reported no remaining Cytosorbents Corp position as of Q2 2020 after selling out during the quarter.
  • Zebra Capital Management sold 11,297 Cytosorbents Corp shares in Q2 2020, an estimated $87K.
  • Zebra Capital Management first reported a position in Cytosorbents Corp in Q1 2020 and held it in 1 quarter.
  • Zebra Capital Management's Cytosorbents Corp position peaked at $87K in Q1 2020.
  • 91 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q2 2020.

Based on Zebra Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.